RTTR - Ritter Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6050
-0.0150 (-2.42%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.6200
Open0.6500
Bid0.610 x 1100
Ask0.630 x 1400
Day's Range0.5884 - 0.6800
52 Week Range0.1830 - 4.0000
Volume509,931
Avg. Volume181,431
Market Cap3.469M
Beta (3Y Monthly)0.90
PE Ratio (TTM)N/A
EPS (TTM)-3.081
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Ritter Pharmaceuticals to Host Expert Call with Dr. William Chey on February 20, 2019

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that Dr. William Chey, Professor of Medicine, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program at the University of Michigan will be the subject of an expert call to be held on February 20, 2019 at 1:00 PM ET/10:00 AM PT.

  • What Type Of Shareholder Owns Ritter Pharmaceuticals, Inc.’s (NASDAQ:RTTR)?
    Simply Wall St.9 days ago

    What Type Of Shareholder Owns Ritter Pharmaceuticals, Inc.’s (NASDAQ:RTTR)?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Read More...

  • GlobeNewswire24 days ago

    Ritter Pharmaceuticals To Present at Noble Capital Markets’ Fifteenth Annual Investor/Equity Conference on January 28, 2019

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that Andrew Ritter, CEO, will be a featured presenter at NobleConXV - Noble Capital Markets’ Fifteenth Annual Investor Conference on January 28th at the W Hotel, Fort Lauderdale, Florida. Mr. Ritter will provide an overview of the company's Phase 3 program in lactose intolerance, including its pivotal Phase 3 trial, “Liberatus” which is currently underway, and other important business highlights.

  • GlobeNewswire2 months ago

    Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that it has passed the 50 percent enrollment point in its first pivotal Phase 3 clinical trial of RP-G28 for the potential treatment of LI, a study known as the “Liberatus” study. “We are pleased to have achieved this important milestone in study enrollment and we remain on track with our projected timeline for the completion of the Liberatus study in the second half of 2019,” said Andrew J. Ritter, CEO of Ritter Pharmaceuticals.

  • GlobeNewswire3 months ago

    Consolidated Research: 2018 Summary Expectations for E*TRADE Financial, Ballantyne Strong, Lincoln Educational Services, Electro-Sensors, Capital Southwest, and Ritter Pharmaceuticals — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.